FLT3/ITD Allelic Ratio Test in UAE | 1000 AED | DHA Licensed Molecular Oncology Lab

Executive Summary & Core Metrics

Accuracy Guarantee: >99.9% diagnostic sensitivity and specificity via ISO 9001:2015 accredited Fragment Analysis (PCR-based capillary electrophoresis).
Logistics Protocol: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
Clinical Guidance: Complimentary Telephonic Post-Test Interpretation with a DHA-Licensed Consultant Medical Geneticist.
Insurance & Billing: Direct billing verification available for major UAE insurers via WhatsApp +971 54 548 8731.
Test Utilization: Essential for risk stratification, prognosis, and targeted therapy selection in Acute Myeloid Leukemia (AML).

Test Overview & Methodology

The FLT3/ITD Allelic Ratio test provides a quantitative measurement of internal tandem duplications (ITD) within the FMS-like tyrosine kinase 3 (FLT3) gene. This molecular biomarker is critical for risk stratification in patients with Acute Myeloid Leukemia (AML) and other high-grade hematologic malignancies. The analysis is performed using high-resolution fragment analysis, which precisely determines the ratio of mutated to wild-type alleles, directly informing therapeutic decisions regarding FLT3 inhibitors.

Comparative Methodology Analysis

Feature	Our Test (FLT3/ITD Allelic Ratio)	Closest Alternative (NGS Panel)
Precision / Methodology	Fragment Analysis (PCR + Capillary Electrophoresis) – gold standard for ITD quantification	Next‑Generation Sequencing (NGS) – qualitative detection, less precise for allelic ratio
Turnaround Time (TAT)	8–10 working days	14–21 working days
Sample Requirements	Bone marrow or peripheral blood (cold-chain transport required)	Often requires bone marrow; blood may be insufficient for sensitive detection

Physician Insight & Safety Protocols

"As a DHA-licensed Consultant Medical Geneticist, I emphasize that the FLT3/ITD allelic ratio is a well-established independent prognostic marker in AML. Accurate quantification of the ratio is essential for identifying patients who may benefit from high-intensity therapy or targeted FLT3 inhibitors. It is crucial, however, that this molecular data is integrated with cytogenetic findings, mutational status (e.g., NPM1), and the patient's overall clinical condition. This test should be ordered by a managing hematologist or oncologist and is not a substitute for a complete diagnostic workup."

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Medication Advisory & Safety Precaution

Do not discontinue prescribed medication without consulting your treating physician. This diagnostic test does not replace therapeutic management or clinical decision-making. All treatment modifications must be made by a qualified hematologist or oncologist based on a comprehensive evaluation of integrated results.

Exclusion Criteria & Emergency Red Flags

Active severe infection or sepsis – postpone collection until the patient is clinically stable.
Platelet count <20 × 10⁹/L without explicit physician clearance due to bleeding risk at the puncture site.
Confirmed pregnancy requiring bone marrow aspiration – requires explicit obstetric and hematology consultation.
Current anticoagulant therapy that cannot be temporarily held – requires specialist approval.
Emergency warning: If you experience sudden high fever, uncontrolled bleeding, or acute confusion, contact your physician immediately or call 998.

Patient FAQ & Clinical Guidance

1. What does the FLT3/ITD Allelic Ratio test detect?

This test specifically detects and quantifies internal tandem duplications in the FLT3 gene. A high allelic ratio (greater than 0.5) is associated with an increased risk of relapse in AML and is a critical factor in determining whether a patient is likely to respond to FLT3 inhibitor therapies such as midostaurin or gilteritinib.

2. How is the sample collected and what are the logistics?

Sample collection requires a bone marrow aspirate or peripheral blood draw performed by a qualified clinician within an accredited hospital setting. Mobile home phlebotomy is not available for this test due to the strict clinical and safety protocols involved. The sample must be transported immediately to the laboratory via temperature-controlled cold-chain logistics.

3. Is a prescription mandatory and does insurance cover this test?

A valid doctor's prescription from a hematologist or oncologist is mandatory for this test. Most comprehensive UAE health insurance plans cover molecular diagnostics for cancer risk stratification. You can send your policy details via WhatsApp to +971 54 548 8731 for instant eligibility verification and direct billing support.

4. What is the turnaround time for results?

The standard turnaround time is 8 to 10 working days from the time the sample is received by the laboratory. This allows for rigorous quality control and validation of the fragment analysis results by our molecular genetics team.

UAE Regulatory & Data Privacy Adherence

DNA Labs UAE strictly complies with the Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical testing safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. We are an ISO 9001:2015 accredited facility (Certificate INT/EGQ/2509DA/3139), ensuring the highest standards of quality management and data security.

Clinical & Logistical Metadata

Test Name	FLT3/ITD Allelic Ratio (Fragment Analysis)
Price (AED)	1,000 AED
Turnaround Time	8 – 10 working days
Sample Type / Matrix	Bone Marrow or Peripheral Blood (Hospital Extraction Only)
Methodology Used	Fragment Analysis (PCR + Capillary Electrophoresis)
ICD-10-CM Code	C92.00 (Acute myeloblastic leukemia, not having achieved remission)
LOINC Code	92806-8 (FLT3 ITD mutation analysis)
DHA Facility License & Address	License No: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE